Home Applications 212122 Application 212122
Type NDA
Sponsor ASTRAZENECA AB Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE AEROSOL, METERED;INHALATION 160MCG/INH; 4.8 MCG/INH; 9MCG/INH Yes No 002 BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE AEROSOL, METERED;INHALATION 0.16MG/INH;0.0048MG/INH;0.018MG/INH Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N212122-001 BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE 0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED / INHALATION RLD, RS 2020-07-23 N212122-002 BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE 0.16MG/INH;0.0048MG/INH;0.018MG/INH AEROSOL, METERED / INHALATION RLD, RS 2026-04-27
Orange Book patents# Current patent rows page 1 of 1 · 18 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N212122-001 10716753 2030-05-28 U-2889 Drug product 2020-08-18 N212122-001 8324266 2030-05-28 U-2889 2020-08-18 N212122-001 8703806 2030-05-28 U-2889 2020-08-18 N212122-001 8808713 2030-05-28 U-2889 Drug product 2020-08-18 N212122-001 9415009 2030-05-28 U-2889 2020-08-18 N212122-001 9463161 2030-05-28 U-2889 Drug product 2020-08-18 N212122-001 8815258 2031-03-17 U-2889 2020-08-18 N212122-001 11331442 2038-10-05 Drug product 2022-06-16 N212122-001 11833292 2038-10-05 Drug product 2023-12-21 N212122-002 10716753 2030-05-28 U-4503 Drug product 2026-05-19 N212122-002 8324266 2030-05-28 U-4503 2026-05-19 N212122-002 8703806 2030-05-28 U-4503 2026-05-19 N212122-002 8808713 2030-05-28 U-4503 Drug product 2026-05-19 N212122-002 9415009 2030-05-28 U-4503 2026-05-19 N212122-002 9463161 2030-05-28 U-4503 Drug product 2026-05-19 N212122-002 8815258 2031-03-17 U-4503 2026-05-19 N212122-002 11331442 2038-10-05 Drug product 2026-05-19 N212122-002 11833292 2038-10-05 Drug product 2026-05-19
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N212122-002 NS 2029-04-27
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 46 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N212122-001 BREZTRI AEROSPHERE 0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED / INHALATION RLD, RS 2020-07-23 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N212122-001 BREZTRI AEROSPHERE 0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED / INHALATION RLD, RS 2020-07-23 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N212122-001 BREZTRI AEROSPHERE 0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED / INHALATION RLD, RS 2020-07-23 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N212122-001 BREZTRI AEROSPHERE 0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED / INHALATION RLD, RS 2020-07-23 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N212122-001 BREZTRI AEROSPHERE 0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED / INHALATION RLD, RS 2020-07-23 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N212122-002 BREZTRI AEROSPHERE 0.16MG/INH;0.0048MG/INH;0.018MG/INH AEROSOL, METERED / INHALATION RLD, RS 2026-04-27 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 10 · 385 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N212122-001 10716753 2030-05-28 U-2889 Drug product 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 8324266 2030-05-28 U-2889 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 8703806 2030-05-28 U-2889 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 8808713 2030-05-28 U-2889 Drug product 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 9415009 2030-05-28 U-2889 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 9463161 2030-05-28 U-2889 Drug product 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 8815258 2031-03-17 U-2889 2020-08-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 11331442 2038-10-05 Drug product 2022-06-16 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-001 11833292 2038-10-05 Drug product 2023-12-21 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 10716753 2030-05-28 U-4503 Drug product 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 8324266 2030-05-28 U-4503 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 8703806 2030-05-28 U-4503 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 8808713 2030-05-28 U-4503 Drug product 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 9415009 2030-05-28 U-4503 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 9463161 2030-05-28 U-4503 Drug product 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 8815258 2031-03-17 U-4503 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 11331442 2038-10-05 Drug product 2026-05-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212122-002 11833292 2038-10-05 Drug product 2026-05-19 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N212122-001 10716753 2030-05-28 U-2889 Drug product 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 8324266 2030-05-28 U-2889 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 8703806 2030-05-28 U-2889 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 8808713 2030-05-28 U-2889 Drug product 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 9415009 2030-05-28 U-2889 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 9463161 2030-05-28 U-2889 Drug product 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 8815258 2031-03-17 U-2889 2020-08-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 11331442 2038-10-05 Drug product 2022-06-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-001 11833292 2038-10-05 Drug product 2023-12-21 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 10716753 2030-05-28 U-4503 Drug product 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 8324266 2030-05-28 U-4503 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 8703806 2030-05-28 U-4503 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 8808713 2030-05-28 U-4503 Drug product 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 9415009 2030-05-28 U-4503 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 9463161 2030-05-28 U-4503 Drug product 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 8815258 2031-03-17 U-4503 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 11331442 2038-10-05 Drug product 2026-05-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212122-002 11833292 2038-10-05 Drug product 2026-05-19 c2088c7a36db…2026-09-14 22:38:34 2026-08 N212122-001 10716753 2030-05-28 U-2889 Drug product 2020-08-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212122-001 8324266 2030-05-28 U-2889 2020-08-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212122-001 8703806 2030-05-28 U-2889 2020-08-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212122-001 8808713 2030-05-28 U-2889 Drug product 2020-08-18 84e616aacf4f…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 3 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0310-4616 BREZTRI budesonide, glycopyrrolate, and formoterol fumarate AstraZeneca Pharmaceuticals LP NDA Current 0310-4616 BREZTRI budesonide, glycopyrrolate, and formoterol fumarate AstraZeneca Pharmaceuticals LP NDA Current 0310-4616 BRETZRI budesonide, glycopyrrolate, and formoterol fumarate AstraZeneca Pharmaceuticals LP NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 85788 SUPPL 2026-05-01 85787 SUPPL 2026-05-01 73957 SUPPL 2023-04-06 68008 ORIG 2021-07-01 64099 ORIG 2020-07-27 64091 ORIG 2020-07-24